Overview of Vaccine Efficacy and Vaccine Effectiveness

Similar documents
Cost-Effectiveness of Influenza Vaccines

Vaccines in Pregnancy MARK H. SAWYER, MD UCSD SCHOOL OF MEDICINE RADY CHILDREN S HOSPITAL SAN DIEGO

INFLUENZA IMMUNIZATION OF REGISTERED NURSES

Influenza Control Program. Frequently Asked Questions Wearing a Mask

Clinical Study Design and Methods Terminology

March ABSTRACT

Chapter 20: Analysis of Surveillance Data

Assertive outreach enhances hepatitis B vaccination for people who inject drugs in Melbourne, Australia

Sample: Policy for the Administration of Influenza Vaccine Employees in Health Care Settings

environics research group

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Vaccination for Pregnant Women

Rapid Critical Appraisal of Controlled Trials

MINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N VACCINE FREQUENTLY ASKED QUESTIONS

Immunization Program: Planning and Forecasting

Influenza Education Presentation Prepared by Peel Public Health 2014

Pandemic Influenza Vaccines: Lessons Learned from the H1N1 Influenza Pandemic

I thank them for their openness, transparency, and willingness to work with WHO to address this newly emerging infection.

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA

FOR INFORMATION CONTACT:

CenteringParenting, a unique group post-partum care and social-support model, is ready for

How To Kill Jesuva

AV1300 STAFF INFLUENZA IMMUNIZATION AND EXCLUSION POLICY

TBE vaccines: immunogenicity, effectiveness and safety

Influenza Surveillance in Thailand 2012

William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016

Updating the Vaccine Injury Table: Legal and Policy Considerations. Elizabeth H. Saindon Senior Attorney Office of the General Counsel, HHS

A Population Based Risk Algorithm for the Development of Type 2 Diabetes: in the United States

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

Intervention and clinical epidemiological studies

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

ACCESS TO THE SEASONAL FLU VACCINE IN CANADA. How the flu shot makes its way from the laboratory to the doctor s office.

Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University

Updating the Vaccine Injury Table: Guillain-Barré Syndrome (GBS) and Seasonal Influenza Vaccines

Environmental Health Science. Brian S. Schwartz, MD, MS

Measles and rubella monitoring

Why Community Engagement?

Immunization Infrastructure: The Role of Section 317

Excess mortality in Europe in the winter season 2014/15, in particular amongst the elderly.

TRINITAS SCHOOL OF NURSING STUDENT HEALTH RECORD

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine

swine flu vaccination:

FAQs on Influenza A (H1N1-2009) Vaccine

VACCINATIONS FOR FOALS

Current Trends in Immunization

Health risk assessment: a standardized framework

Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) (908)

Chapter 3. Sampling. Sampling Methods

VACCINATIONS FOR ADULT HORSES

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS

NSW Pertussis Control Program 2015

Music-Based Interventions and the Resilience of Persons with Dementia

4/30/2013 HPV VACCINE AND NORTH DAKOTA HPV IMMUNIZATION RATES HUMAN PAPILLOMAVIRUS (HPV) HUMAN PAPILLOMAVIRUS HPV CONTINUED

Healthcare Personnel Safety Component. Healthcare Personnel Vaccination Module Influenza Vaccination Summary. Inpatient Rehabilitation Facilities

Clinical Infectious Diseases Advance Access published February 28, 2013

Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.

Background paper for SAGE discussions. SAGE non-specific effects of vaccines Working Group

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Influenza Vaccine Frequently Asked Questions. Influenza Control Program

Ontario Pandemic Influenza Plan for Continuity of Electricity Operations

How To Write A Systematic Review

Data Management considerations in Observational studies

Chapter 6 The Specialty of Gerontological Nursing

Key Facts about Influenza (Flu) & Flu Vaccine

Guidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis

Pfizer MedEd Grant ID

Risk Management Plan (RMP) Guidance (Draft)

Vaccination against pertussis (Whooping cough) for pregnant women Information for healthcare professionals

Facts About Chickenpox and Shingles for Adults

Home Healthcare Solutions. Don Spence CEO Home Healthcare Solutions Philips Healthcare

Ten Good Reasons to Be Concerned about the Human Papillomavirus (HPV) Vaccination Campaign

Competency 1 Describe the role of epidemiology in public health

Real World Data: How It s Used at a Medical Device Company

Transcription:

Overview of Vaccine Efficacy and Vaccine Effectiveness Shelly McNeil, MD Canadian Center for Vaccinology Dalhousie University Halifax, Nova Scotia Canada

Efficacy vs Effectiveness Vaccine efficacy- % reduction in disease incidence in a vaccinated group compared to an unvaccinated group under optimal conditions (eg RCT) Typically use objective outcomes- eg labconfirmed influenza designed to maximize internal validity (by randomization and allocation concealment) often at the expense of generalizability

Vaccine effectiveness- ability of vaccine to prevent outcomes of interest in the real world Primary care settings Less stringent eligibility Assessment of relevant health outcomes Clinically relevant treatment selection and followup duration Assessment of relevant adverse events Adequate sample size to detect clinically relevant differences Intention to treat analysis Agency for Healthcare Research and Policy, US Dept HHS, 2006

Why monitor vaccine effectiveness?

Burden of Disease Vaccine Effectiveness Optimal disease prevention Clinical trials Policy and Program

Demonstrating need (Burden of disease) and proving benefit (Vaccine effectiveness) is critical to promote immunization, sustain uptake, and stimulate development of better vaccines

Informing Cost effectiveness Cost of Disease Cost of vaccination Where the balance rests depends upon understanding the proportion of the disease burden that is vaccine preventable = VACCINE EFFECTIVENESS At any vaccine cost, the greater the burden of disease and the greater the proportion that is vaccine preventable, the more Cost effective a program will be

Factors impacting vaccine effectiveness Host factors Age Comorbidity- including frailty/function Prior exposure Time since vaccination Vaccine characteristics Mode of delivery Live vs inactivated Vaccine composition- addition of adjuvant Match to circulating strains

Optimal VE Data to inform decisionmaking Overall and type/subtype specific (including B-lineages) By age group Against non-severe and severe outcomes In specific at-risk/target populations By vaccine type- are new vaccines really better? Real-time- throughout season- may predict drift, circulating mismatched strains, duration of protection

Define Outcome- what is important? ILI/ARI Serious outcomes- hospitalization +/- death, dependence Lab-confirmed influenza Careful attention/adherence to case definition specificity more important than sensitivity!

Measuring Vaccine Effectiveness- Data needs Surveillance data for outcome of interest (case ascertainment) Enhance routine testing for influenza! Immunization data: Vaccinated? When? (in relation to onset of disease) Which vaccine? Clinical data: age, gender, comorbidity (including pregnancy), functional status, course and outcome

The problem of BIAS- how do vaccinated and unvaccinated people differ? Bias is any factor independently associated with risk of disease and vaccination status Healthy user bias- persons more likely to be vaccinated are less likely to develop disease- OVER-estimates VE Frailty bias- persons more likely to be vaccinated (frail elderly in LTCF) are more likely to experience adverse influenza outcomes- UNDER-estimates VE

Observational methods for estimating vaccine effectiveness Cohort studies Case-control studies ( test-negative case control) Household contact studies Screening method- compare proportion of cases vaccinated to proportion of a comparable group in the population who are vaccinated useful if vaccination status is only known in people with the outcome- need to know population coverage rates

So How effective are influenza vaccines?? (Osterholm, Lancet ID Jan 2012) Adults 18-65y (TIV) Children 6mos-7y (LAIV) 59% (51-67%) 83% (69-91%)

What about the elderly? (Cochrane Library, Feb. 2010) Only 1 RCT identified- underpowered to assess efficacy Point estimates difficult to interpret due to uncontrolled bias No conclusion could be drawn

Nichol et al. NEJM Oct 2007 27% (23-32%)

48% (45-50%)

Conclusions Monitoring vaccine effectiveness is critical to: Optimize use of limited resources Demonstrate impact of vaccine on health outcomes (justify cost) Optimize vaccine uptake Stimulate development of improved vaccines

Thank you!